Extensive-Stage Small Cell Lung CancerPhase 3NCT06646276

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

A Phase 3 study testing BMS-986489 (Atigotatug+Nivolumab), Atezolizumab and Carboplatin in people with Extensive-Stage Small Cell Lung Cancer, run by Bristol-Myers Squibb at 183 sites in 26 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer. Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Extensive-Stage Small Cell Lung Cancer
What is being tested?: BMS-986489 (Atigotatug+Nivolumab), Atezolizumab and Carboplatin
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 530 participants
Where: 183 sitesin 26 countries
Study dates: 25 Feb 2025to 14 Jul 2031
Phase: Phase 3

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale.
Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system

Who cannot join

Participants have already received certain types of treatment for extensive stage small cell lung cancer
Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy
Other protocol-defined Inclusion/Exclusion criteria apply.

Trial locations and contacts

183 sites in 26 countries. Contact the study team or a site near you to ask about taking part.

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com contact

855-907-3286

Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #. contact

Country

City, postcode or hospital

Sites recruiting now only

183 sites in 26 countries

China23 sites, 1 recruiting

Local Institution - 0204
Beijing, Beijing Municipality, 100142
Completed
Local Institution - 0336
Beijing, Beijing Municipality, 101149
Active, not recruiting
Local Institution - 0244
Changchun, Jilin, 132000
Active, not recruiting
Local Institution - 0216
Changsha, Hunan, 410013
Completed
Local Institution - 0330
Chengdu, Sichuan, 610041
Active, not recruiting
Local Institution - 0203
Chongqing, Chongqing Municipality, 400030
Active, not recruiting
Local Institution - 0308
Fuzhou, Fujian, 350014
Active, not recruiting
Local Institution - 0236
Hangzhou, Zhejiang, 310016
Active, not recruiting
Local Institution - 0237
Hangzhou, Zhejiang, 310022
Active, not recruiting
Local Institution - 0227
Harbin, Heilongjiang, 150081
Active, not recruiting
Local Institution - 0200
Jinan, Shandong, 250117
Active, not recruiting
Local Institution - 0229
Linhai, Zhejiang, 317000
Completed
Local Institution - 0233
Nanchang, Jiangxi, 330006
Active, not recruiting
Local Institution - 0206
Shanghai, Shanghai Municipality, 200030
Active, not recruiting
Local Institution - 0210
Shanghai, Shanghai Municipality, 200032
Active, not recruiting
Local Institution - 0186
Shanghai, Shanghai Municipality, 200120
Active, not recruiting
Local Institution - 0234
Shantou, Guangdong, 515000
Active, not recruiting
Local Institution - 0235
Shenyang, Liaoning, 110042
Site 0235
Not yet recruiting
Local Institution - 0213
Tianjin, Tianjin Municipality, 300060
Active, not recruiting
Local Institution - 0209
Wuhan, Hubei, 430079
Active, not recruiting
Local Institution - 0208
Wuhan, Hubei, 430100
Active, not recruiting
Local Institution - 0335
Xi'an, Shaanxi, 710126
Completed
Local Institution - 0212
Xiamen, Fujian, 361003
Completed

Other trials in China

United States20 sites, 18 recruiting

University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico, 87106
Moises Harari-Turquie, Site 0033, 505-570-5835
Recruiting
Texas Oncology - Central/South Texas
Austin, Texas, 78705
James Uyeki, Site 0001, 512-427-9400
Recruiting
Sanford Medical Center
Bismarck, North Dakota, 58501
Thandiwe Gray, Site 0232, 701-323-5741
Recruiting
Oncology Hematology Care
Cincinnati, Ohio, 45242
Patrick Ward, Site 0284, 513-751-2273
Recruiting
Southern Cancer Center, PC
Daphne, Alabama, 36526
Michael Meshad, Site 0337, 111-111-1111
Recruiting
Duke Cancer Institute
Durham, North Carolina, 27710
Neal Ready, Site 0029, 919-684-8239
Recruiting
Swedish Cancer Institute - Edmonds
Edmonds, Washington, 98026
Siddhartha Devarakonda, Site 0339, 206-386-2457
Recruiting
Sanford Fargo Medical Center
Fargo, North Dakota, 58102
Mark Gitau, Site 0010, 000-000-0000
Recruiting
Florida Cancer Specialists - South
Fort Myers, Florida, 33901
Alexander Glick, Site 0245, 239-274-9930
Recruiting
Local Institution - 0283
Hot Springs, Arkansas, 71913
Completed
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
Marietta, Georgia, 30060
Walid Shaib, Site 0013, 770-281-5124
Recruiting
Local Institution - 0037
Minneapolis, Minnesota, 55407
Withdrawn
SCRI Oncology Partners
Nashville, Tennessee, 37203
Melissa Johnson, Site 0008, 615-329-7274
Recruiting
Mid Florida Hematology and Oncology Center
Orange City, Florida, 32763
Santosh Nair, Site 0009, 407-353-1915
Recruiting
Illinois Cancer Care
Peoria, Illinois, 61615
Gary MacVicar, Site 0019, 309-243-3000
Recruiting
Oncology & Hematology Associates of Southwest Virginia, Inc.
Roanoke, Virginia, 24014
Jerome Goldschmidt, Site 0246, 540-381-5291
Recruiting
Swedish Medical Center
Seattle, Washington, 98104
Siddhartha Devarakonda, Site 0026, 206-386-2457
Recruiting
Sanford Cancer Center
Sioux Falls, South Dakota, 57104
Allison Watson, Site 0231, 605-209-4092
Recruiting
Florida Cancer Specialists - North
St. Petersburg, Florida, 33705
Maen Hussein, Site 0020, 727-216-1143
Recruiting
Texas Oncology - Northeast Texas
Tyler, Texas, 75702
Sarah Wang, Site 0281, 903-579-9800
Recruiting

Other trials in United States

Japan18 sites

Local Institution - 0326
Bunkyo-ku, Tokyo, 1138603
Active, not recruiting
Local Institution - 0327
Fukushima, 960-1295
Active, not recruiting
Local Institution - 0322
Hamamatsu, Shizuoka, 431-3192
Active, not recruiting
Local Institution - 0320
Hidaka, Saitama, 350-1298
Active, not recruiting
Local Institution - 0317
Hirakata, Osaka, 573-1191
Active, not recruiting
Local Institution - 0318
Ina-machi, Saitama, 362-0806
Active, not recruiting
Local Institution - 0321
Kanazawa, Ishikawa-ken, 920-8641
Active, not recruiting
Local Institution - 0324
Kashihara, Nara, 634-8522
Completed
Local Institution - 0323
Kobe, Hyōgo, 650-0047
Active, not recruiting
Local Institution - 0315
Koto, Tokyo, 135-8550
Active, not recruiting
Local Institution - 0328
Kurashiki, Okayama-ken, 710-8602
Active, not recruiting
Local Institution - 0292
Kurume, Fukuoka, 830-0011
Active, not recruiting
Local Institution - 0319
Matsuyama, Ehime, 791-0280
Active, not recruiting
Local Institution - 0314
Ōsaka-sayama, Osaka, 589-8511
Active, not recruiting
Local Institution - 0313
Sapporo, Hokkaido, 0608648
Active, not recruiting
Local Institution - 0291
Sendai, Miyagi, 9810914
Active, not recruiting
Local Institution - 0325
Takatsuki, Osaka, 569-8686
Completed
Local Institution - 0316
Yokohama, Kanagawa, 236-0051
Completed

Other trials in Japan

France10 sites

Local Institution - 0047
Créteil, Val-de-Marne, 94010
Completed
Local Institution - 0044
Gleizé, Rhône, 69400
Completed
Local Institution - 0040
La Tronche, Isère, 38700
Active, not recruiting
Local Institution - 0052
Lille, Nord, 59037
Completed
Local Institution - 0043
Marseille, 13915
Active, not recruiting
Local Institution - 0048
Montpellier, Hérault, 34090
Completed
Local Institution - 0050
Paris, 75248
Active, not recruiting
Local Institution - 0051
Pierre-Bénite, Rhône, 69310
Active, not recruiting
Local Institution - 0215
Quimper, 29000
Active, not recruiting
Local Institution - 0038
Villejuif, Val-de-Marne, 94800
Active, not recruiting

Other trials in France

Spain10 sites

Local Institution - 0294
Barcelona, Catalunya [Cataluña], 08036
Completed
Local Institution - 0302
Barcelona, Catalunya [Cataluña], 08041
Active, not recruiting
Local Institution - 0301
Jaén, Jaén, 23007
Active, not recruiting
Local Institution - 0298
Madrid, Madrid, Comunidad de, 28034
Active, not recruiting
Local Institution - 0296
Madrid, Madrid, Comunidad de, 28041
Active, not recruiting
Local Institution - 0297
Majadahonda, Madrid, Comunidad de, 28222
Active, not recruiting
Local Institution - 0300
Santiago de Compostela, A Coruña [La Coruña], 15706
Active, not recruiting
Local Institution - 0299
Seville, 41009
Active, not recruiting
Local Institution - 0295
Seville, 41013
Completed
Local Institution - 0303
Valencia, Valenciana, Comunitat, 46014
Completed

Other trials in Spain

Germany9 sites

Local Institution - 0257
Bad Berka, Thuringia, 99437
Active, not recruiting
Local Institution - 0261
Cologne, North Rhine-Westphalia, 51109
Active, not recruiting
Local Institution - 0256
Frankfurt am Main, Hesse, 60488
Active, not recruiting
Local Institution - 0258
Gauting, 82131
Completed
Local Institution - 0259
Großhansdorf, 22927
Active, not recruiting
Local Institution - 0265
Halle, Saxony-Anhalt, 06120
Active, not recruiting
Local Institution - 0260
Heidelberg, 69126
Active, not recruiting
Local Institution - 0262
Oldenburg, Lower Saxony, 26121
Active, not recruiting
Local Institution - 0264
Stuttgart, 70736
Active, not recruiting

Other trials in Germany

Brazil7 sites

Local Institution - 0178
Barretos, São Paulo, 14784400
Active, not recruiting
Local Institution - 0166
Fortaleza, Ceará, 60135-237
Active, not recruiting
Local Institution - 0163
Itajaí, Santa Catarina, 88301-220
Active, not recruiting
Local Institution - 0165
Porto Alegre, Rio Grande do Sul, 90035-903
Active, not recruiting
Local Institution - 0169
Porto Alegre, Rio Grande do Sul, 90610-000
Active, not recruiting
Local Institution - 0170
Santa Cruz do Sul, Rio Grande do Sul, 96830-180
Completed
Local Institution - 0111
São Paulo, São Paulo, 01509-010
Active, not recruiting

Other trials in Brazil

Italy7 sites

Local Institution - 0074
Bologna, 40138
Active, not recruiting
Local Institution - 0068
Milan, Lombardy, 20133
Active, not recruiting
Local Institution - 0067
Milan, 20141
Active, not recruiting
Local Institution - 0072
Naples, Campania, 80131
Active, not recruiting
Local Institution - 0110
Perugia, Umbria, 06132
Active, not recruiting
Local Institution - 0070
Peschiera del Garda, Verona, 37019
Completed
Local Institution - 0069
Rome, Roma, 00144
Active, not recruiting

Other trials in Italy

Romania7 sites

Local Institution - 0133
Bucharest, Bucharest, 013812
Completed
Local Institution - 0135
Bucharest, Bucharest, 022328
Active, not recruiting
Local Institution - 0141
Cluj-Napoca, 400015
Active, not recruiting
Local Institution - 0140
Craiova, Dolj, 200542
Active, not recruiting
Local Institution - 0137
Florești, Cluj, 407280
Active, not recruiting
Local Institution - 0139
Iași, 700106
Active, not recruiting
Local Institution - 0132
Iași, 700483
Active, not recruiting

Other trials in Romania

South Korea6 sites

Local Institution - 0305
Cheongju-si, Chungcheongbuk-do [Chungbuk], 28644
Active, not recruiting
Local Institution - 0309
Daegu, Taegu-Kwangyǒkshi, 42601
Active, not recruiting
Local Institution - 0286
Seongnam, Kyǒnggi-do, 13620
Completed
Local Institution - 0285
Seoul, Seoul-teukbyeolsi [Seoul], 03722
Active, not recruiting
Local Institution - 0293
Seoul, Seoul-teukbyeolsi [Seoul], 05505
Active, not recruiting
Local Institution - 0304
Suwon, Kyǒnggi-do, 16499
Active, not recruiting

Other trials in South Korea

Argentina5 sites

Local Institution - 0077
ABB, Buenos Aires F.D., C1199ABB
Completed
Local Institution - 0100
Buenos Aires, Buenos Aires F.D., C1417DTB
Withdrawn
Local Institution - 0080
CABA, Buenos Aires F.D., C1430EGF
Active, not recruiting
Local Institution - 0079
Ciudad Autónoma de Buenos Aires, Buenos Aires, C1426ANZ
Completed
Local Institution - 0094
Río Cuarto, Córdoba Province, X5800AEV
Active, not recruiting

Other trials in Argentina

Australia5 sites

Local Institution - 0190
Ballarat Central, Victoria, 3350
Completed
Local Institution - 0105
Brisbane, Queensland, 4120
Active, not recruiting
Local Institution - 0202
Campbelltown, New South Wales, 2560
Active, not recruiting
Local Institution - 0175
Murdoch, Western Australia, 6150
Active, not recruiting
Local Institution - 0106
Penrith, New South Wales, 2750
Active, not recruiting

Other trials in Australia

Chile5 sites

Local Institution - 0086
Santiago, Santiago Metropolitan, 0
Active, not recruiting
Local Institution - 0085
Santiago, Santiago Metropolitan, 7500921
Active, not recruiting
Local Institution - 0083
Santiago, Santiago Metropolitan, 8330032
Completed
Local Institution - 0084
Santiago, Santiago Metropolitan, 8420383
Active, not recruiting
Local Institution - 0082
Viña del Mar, Valparaiso, 2520598
Active, not recruiting

Other trials in Chile

Greece5 sites

Local Institution - 0063
Athens, Attikí, 115 26
Active, not recruiting
Local Institution - 0064
Athens, Attikí, 115 27
Active, not recruiting
Local Institution - 0059
Larissa, Thessalía, 41110
Completed
Local Institution - 0062
Thessaloniki, Kentrikí Makedonía, 540 07
Completed
Local Institution - 0058
Thessaloniki, Thessaloníki, 570 01
Active, not recruiting

Other trials in Greece

India5 sites

Local Institution - 0274
Bengaluru, Karnataka, 560017
Active, not recruiting
Local Institution - 0273
Kolkata, West Bengal, 700094
Completed
Local Institution - 0271
Madurai, Tamil Nadu, 625107
Completed
Local Institution - 0278
New Delhi, National Capital Territory of Delhi, 110029
Withdrawn
Local Institution - 0277
Varanasi, Uttar Pradesh, 221005
Active, not recruiting

Other trials in India

Poland5 sites

Local Institution - 0195
Bydgoszcz, 85796
Active, not recruiting
Local Institution - 0193
Konin, Greater Poland Voivodeship, 62-500
Active, not recruiting
Local Institution - 0189
Lodz, Łódź Voivodeship, 93-338
Active, not recruiting
Local Institution - 0241
Poznan, Greater Poland Voivodeship, 60-192
Active, not recruiting
Local Institution - 0192
Prabuty, Pomeranian Voivodeship, 82-550
Active, not recruiting

Other trials in Poland

Turkey (Türkiye)5 sites

Local Institution - 0154
Adana, 01370
Active, not recruiting
Local Institution - 0157
Ankara, 06010
Active, not recruiting
Local Institution - 0177
Ankara, 06280
Active, not recruiting
Local Institution - 0158
Çiğli, İzmir, 35620
Active, not recruiting
Local Institution - 0153
Istanbul, 34732
Active, not recruiting

Other trials in Turkey (Türkiye)

Austria4 sites

Local Institution - 0253
Graz, Styria, 8036
Active, not recruiting
Local Institution - 0252
Linz, 4021
Active, not recruiting
Local Institution - 0255
Rankweil, 6830
Active, not recruiting
Local Institution - 0251
Wels, Upper Austria, 4600
Completed

Other trials in Austria

Belgium4 sites

Local Institution - 0198
Brussels, Bruxelles-Capitale, Région de, 1200
Active, not recruiting
Local Institution - 0091
Ghent, Oost-Vlaanderen, 9000
Active, not recruiting
Local Institution - 0092
Liège, 4000
Active, not recruiting
Local Institution - 0187
Sint-Niklaas, Oost-Vlaanderen, B-9100
Active, not recruiting

Other trials in Belgium

Canada4 sites

Local Institution - 0290
Chicoutimi, Quebec, G7H 5H6
Active, not recruiting
Local Institution - 0289
Edmonton, Alberta, T6G 1Z2
Active, not recruiting
Local Institution - 0288
Québec, Quebec, G1V 4G5
Active, not recruiting
Local Institution - 0287
Rimouski, Quebec, G5L 5T1
Completed

Other trials in Canada

Czechia4 sites

Local Institution - 0114
Brno, Brno-město, 656 53
Active, not recruiting
Local Institution - 0116
Olomouc, 779 00
Active, not recruiting
Local Institution - 0117
Ostrava, Ostrava Město, 703 00
Active, not recruiting
Local Institution - 0113
Prague, Praha 4, 14059
Active, not recruiting

Other trials in Czechia

United Kingdom4 sites

Local Institution - 0159
Aberdeen, AB9 2ZB
Completed
Local Institution - 0183
Central Middlesbrough, Middlesbrough, TS4 3BW
Completed
Local Institution - 0101
Manchester, M20 4BX
Active, not recruiting
Local Institution - 0226
Metropolitan Borough of Wirral, CH63 4JY
Active, not recruiting

Other trials in United Kingdom

Malaysia3 sites

Local Institution - 0310
Kuala Lumpur, Kuala Lumpur, 50586
Completed
Local Institution - 0312
Kuala Lumpur, Kuala Lumpur, 50603
Completed
Local Institution - 0311
Kuching, Sarawak, 93586
Active, not recruiting

Other trials in Malaysia

Netherlands3 sites

Local Institution - 0097
Amsterdam, North Holland, 1081 HV
Completed
Local Institution - 0099
Arnhem, 6815 AD
Active, not recruiting
Local Institution - 0098
Groningen, 9713 GZ
Active, not recruiting

Other trials in Netherlands

Switzerland3 sites

Local Institution - 0248
Chur, 7000
Active, not recruiting
Local Institution - 0249
Winterthur, 8401
Active, not recruiting
Local Institution - 0247
Zurich, 8091
Active, not recruiting

Other trials in Switzerland

Mexico2 sites

Local Institution - 0146
Guadalajara, Jalisco, 44630
Active, not recruiting
Local Institution - 0145
Puebla City, 72424
Completed

Other trials in Mexico

About this study

Official title: A Randomized, Double Blind, Multicenter Phase 3 Trial of BMS-986489 (Atigotatug+Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide vs Atezolizumab in Combination With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Conditions: Extensive-Stage Small Cell Lung Cancer
Being tested: BMS-986489 (Atigotatug+Nivolumab), Atezolizumab, Carboplatin, Etoposide
Keywords: BMS-986489, BMS-986012, Extensive-Stage Small Cell Lung Cancer, Etoposide, Carboplatin, Nivolumab, TIGOS, fucGM1, SCLC, ES-SCLC, atigotatug
Medical subject headings: Small Cell Lung Carcinoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

BMS-986489 (Atigotatug+Nivolumab)Biological
Specified dose on specified days
AtezolizumabBiological
Specified dose on specified days
CarboplatinDrug
Specified dose on specified days
EtoposideDrug
Specified dose on specified days

Study groups in NCT06646276
Study group	Role	What they receive
Arm A	Experimental	Not described Receives: Biological: BMS-986489 (Atigotatug+Nivolumab); Drug: Carboplatin; Drug: Etoposide
Arm B	Active comparator	Not described Receives: Biological: Atezolizumab; Drug: Carboplatin; Drug: Etoposide

What is being measured

The primary outcome is the main question the study is designed to answer.

Overall Survival (OS)
Measured: Up to 5 years

Secondary outcomes (7)

Time to definitive deterioration (TTDD)based on the LCSS ASBI defined as the time from randomization until a definitive clinically meaningful decline (≥ 10 point increase from baseline in LCSS ASBI score).
Measured: Up to 5 years
Number of participants with Adverse Events (AEs)
Measured: Up to 135 days after last treatment
Number of Participants with Serious Adverse Events (SAEs)
Measured: Up to 135 days after last treatment
Number of Participants with Adverse Events (AEs) leading to discontinuation and death
Measured: Up to 135 days after last treatment
Objective Response (OR)
Measured: Up to 5 years
Duration of Response (DOR)
Measured: Up to 5 years
Progression Free Survival (PFS)
Measured: Up to 5 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

25 Feb 202514 Jul 2031

First posted17 Oct 2024
Study start25 Feb 2025
Primary completion17 Aug 2027 (estimated)
Study completion14 Jul 2031 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Extensive-Stage Small Cell Lung CancerStudies of the same condition, open and under way.
More trials run by Bristol-Myers SquibbThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase 3
Primary purpose: Treatment
Allocation: Randomised
Intervention model: Parallel groups
Masking: Quadruple blind
Who is masked: Participant, Care provider, Investigator, Outcomes assessor
Enrolment: 530 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06646276
Sponsor's protocol ID: CA245-0001
Other IDs: 2024-515740-23, U1111-1308-1151
Status last verified: Oct 2026
First submitted: 16 Oct 2024
Last updated: 13 Oct 2026
Results posted: No
Data monitoring committee: Yes
FDA-regulated drug: Yes
FDA-regulated device: No
Individual data sharing: Yes: BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Interested in taking part?

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286

Clinical.Trials@bms.com

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

Active, not recruitingPhase 2
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
Extensive-stage Small Cell Lung Cancer
Not yet recruitingPhase 1
A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
RecruitingPhase 1
A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)
Active, not recruitingPhase 2
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
Extensive Stage Small Cell Lung Cancer
RecruitingPhase 1
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
Recurrent Small Cell Lung Cancer, Extensive-Stage Small Cell Lung Cancer

All Extensive-Stage Small Cell Lung Cancer trials